Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tafamidis
Drug ID BADD_D02107
Description Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Indications and Usage Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.[A189708,A189711,L11280]
Marketing Status approved; investigational
ATC Code N07XX08
DrugBank ID DB11644
KEGG ID D09673
MeSH ID C547076
PubChem ID 11001318
TTD Drug ID D04DFR
NDC Product Code 60715-0647; 59651-743; 66039-960; 73435-031; 14501-0102; 58159-079; 60715-4344; 0069-8730; 11014-0390; 69988-0039
UNII 8FG9H9D31J
Synonyms tafamidis | Vyndamax | Vyndaqel | FX 1006A | FX1006A | FX-1006A | tafamidis meglumine
Chemical Information
Molecular Formula C14H7Cl2NO3
CAS Registry Number 594839-88-0
SMILES C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vertebral foraminal stenosis17.10.01.024; 15.01.08.0150.000538%Not Available
Systolic dysfunction02.04.02.0350.000538%Not Available
Lumbosacral radiculopathy17.10.03.0050.000538%Not Available
Acquired ATTR amyloidosis10.02.05.0060.001615%Not Available
Bendopnoea22.02.01.034; 02.11.05.0020.001077%Not Available
Cardiac dysfunction02.11.01.0040.000808%Not Available
Dilated cardiomyopathy02.04.01.0170.000538%Not Available
Disease complication08.01.03.0870.000538%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.004199%Not Available
Gait inability17.02.05.069; 08.01.02.0110.002153%Not Available
Illness08.01.03.0910.005922%Not Available
Left ventricular dilatation02.04.02.0440.000538%Not Available
Normocytic anaemia01.03.02.0220.000538%Not Available
Obstructive sleep apnoea syndrome22.02.01.038; 19.02.05.012; 17.15.05.0030.001346%Not Available
Phrenic nerve paralysis17.01.04.0240.000538%Not Available
Physical deconditioning08.01.03.0960.001884%Not Available
Right ventricular dilatation02.04.02.050--Not Available
Skin weeping23.03.03.1010.001184%Not Available
Spinal claudication24.04.06.050; 17.10.01.0300.000538%Not Available
Spinal stenosis15.10.04.014; 17.10.01.0310.003445%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.002638%Not Available
The 10th Page    First    Pre   10    Total 10 Pages